Our vision is to provide breakthrough, tumor-directed immunotherapeutics to areas with high unmet medical needs and where an immune-mediated anti-tumor response can make a difference by improving anti-tumor efficacy and reducing immune-related side effects. Immuneed is in premises with fully integrated infrastructure and lab capabilities in Uppsala, Sweden.
We have developed a proprietary technology platform, the TET-platform™, which can be used for multiple indications. Focus with our first drug candidate is early stage intermediate to high-risk prostate cancer. The unique composition of our vaccine complex allows us to create the next generation synthetic peptide vaccine products. Initial seed funding is secured, but further funding is needed early 2018.